h3b-6545
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 17, 2017 (NCT03250676)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Estrogen receptor alphaANTAGONIST
ESR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C(=O)/C=C/CNCCOc1ccc(/C(=C(/CC(F)(F)F)c2ccccc2)c2ccc3[nH]nc(F)c3c2)cn1.Cl- Mol. weight
- 604.05 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068514 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04568902 | Phase 1 | Sep 30, 2020 | Eisai |
| NCT04288089 | Phase 1 | Mar 31, 2020 | Eisai |
| NCT03250676 | Phase 1/Phase 2 (Phase 2) | Aug 17, 2017 | Eisai |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 3 | 3 | 2 | 2017 |
1 organizations
Page 1 / 1